Actinium Announces Further Development of Actimab-A Manufacturing Wall Street Journal The Company's lead radiopharmaceutical Iomab(TM)-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study ... |
